Getinge Q4 Net Profit Up, But Sales & Order Intake Down; Sees Organic Sales Growth In FY26

Getinge reported Q4 net profit of SEK 869m (vs. SEK 668m a year ago) and EPS of SEK 3.19 (2.44), while adjusted net profit fell to SEK 1.21bn (SEK 1.44bn) and adjusted EPS to SEK 4.45 (5.28). Adjusted EBITA declined to SEK 1.81bn (2.14bn) with an adjusted EBITA margin of 17.8% (19.4%), though excluding currency and tariff effects the margin was 20.3%. Net sales slipped to SEK 10.19bn (11.07bn) and order intake to SEK 8.56bn (9.27bn), but organic net sales and order intake rose 1.2% and 2.3% respectively. For fiscal 2026 the company guides to 3–5% organic growth (adjusted for the phase-out of Surgical Perfusion) amid high geopolitical uncertainty, and the board has proposed a higher dividend of SEK 4.75 per share (prior SEK 4.60).

Analysis

Contrarian angles: Consensus may be overstating structural demand loss — adjusted EBITA ex-FX/tariffs of 20.3% suggests operational leverage that’s being ignored; if organic growth reaches the guidance midpoint (~4%) and margins re-expand >150–250 bps, upside of 15–25% in 6–12 months is plausible. Conversely, reaction is underdone if tariffs/geo-risk persist; set hard sell signals (order intake rolling 2-quarter decline >10% or adjusted EBITA margin below 17%) that would invalidate the bullish view.

Key Decisions for Investors

• Establish a 2–3% long position in Getinge (GETI-B.ST or OTC: GNGBF) within 2 weeks to capture dividend record mechanics (record date Apr 23) and hold 6–12 months; add incrementally if adjusted EBITA margin (ex-FX/tariffs) reverts above 19% or if organic sales >3.5% on a rolling-quarter basis.
• Implement a directional options sleeve: buy a Jun 2026 call spread (roughly 0–10% OTM buy / 15–25% OTM sell) sized to 1–2% notional as asymmetric upside exposure; cut if spread value falls >50% from purchase or if order intake declines >10% y/y over two consecutive quarters.
• Pair trade: go long Getinge 2% weight and short Stryker (SYK) or Medtronic (MDT) 1% weight to capture relative recovery in European hospital equipment versus larger elective-heavy US peers; rebalance if beta-adjusted P&L diverges >8% over 3 months.
• Reduce exposure by 3–5% to high-multiple elective-surgery names (e.g., companies with >30% revenue sensitivity to elective volumes) and rotate into defensive medtech/sterilization names if SEK weakens >3% or tariffs persist — this rotation should be executed within 1 month.